Phase II trial of cediranib (AZD2171) in docetaxel-resistant, castrate-resistant prostate cancer (CRPC)

5136 Introduction: There is no standard therapy for prostate cancer patients who have progressed following docetaxel therapy. VEGF is implicated in tumor blood vessel formation and disease progression in solid tumors. Cediranib, an oral, small molecule inhibitor of VEGF receptor tyrosine kinases, is being evaluated at a dose of 20 mg daily in patients with prostate cancer resistant to docetaxel and hormonal therapy. Methods: Patients have clinical and/or radiographic evidence of progression on docetaxel with no limit on the number of prior chemotherapy regimens or radioisotopes. Response imaging is assessed every 2 months. Simon two stage optimal design was utilized. Primary objective is a 30% 6 month probability of progression free survival as determined by clinical (not PSA rise alone) and radiographic criteria. If 2 or more patients are progression-free at 6 months, the cohort will be expanded to 35 evaluable patients. Patients receiving cediranib were scanned by DCE-MRI pre- and post-treatment. A two ...